姓名：叶娜
职务职称：博士，特聘副教授，硕士生导师
联系电话：
联系邮箱：yena@suda.edu.cn
联系地址：苏州市工业园区仁爱路199号药学院云轩楼1225
个人简介：
一、 学习与工作经历
2016.9–至今：苏州大学，药学院，特聘副教授
2013.6–2016.8：美国德州大学医学分部，博士后
2008.09-2013.06：中国科学院上海药物研究所，药物化学，理学博士
2004.09-2008.07：沈阳药科大学，国家基础药学理科基地班，理学学士
二、 研究方向
1）靶向神经精神性重大疾病的药物研发
2）抗肿瘤药物的设计与合成
3) 有机方法学在药物研发中的应用

三、 主要学术科研成果

目前主持国家自然科学基金青年项目(**)和江苏省自然科学基金项目(BK**)各1项，还曾参与美国NIH、CPRIT等项目研究，至今发表SCI论文30余篇，其中第一作者12篇。参与申报国际发明专利2项、中国发明专利5项，其中1项中国专利已授权。并编写专著《新药研发案例研究：明星药物如何从实验室走向市场》第十章-氟西汀。2011年，获得“全国药物化学学术会议优秀墙报奖”；2013年，获得“中国科学院院长奖学金优秀奖”及“中国科学院优秀毕业生”等奖励；另外，设计开发的靶向聚腺苷二磷酸核糖聚合酶PARP抑制剂SOMCL-9112作为抗肿瘤候选药物，已申报化学药品1.1类新药—希明哌瑞及其片剂，经CFDA快速审批，已获得临床实验批件，目前正在临床I期研究中（NCT**）。

代表性论文如下：
1) Yuan, B.; Ye, N.;^#Song, S. S.; Wang, Y. T.; Song, Z.; Chen, H. D.; Chen, C. H.; Huan, X. J.; Wang, Y. Q.; Su, Y.; Shen, Y. Y.; Sun, Y. M.; Yang, X. Y.; Chen, Y.; Guo, S. Y.; Gan, Y.; Gao, Z. W.; Chen, X. Y.; Ding, J.; He, J. X.; Zhang, A.;Miao, Z. H.Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer lett., 2017,386, 47-56.(^#并列第一作者)
2) Ye, N.; Zhu, Y.; Liu, Z.; Mei, F. C.; Chen, H.; Wang, P.; Cheng, X.; Zhou, J. Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists. Eur. J. Med. Chem. 2017,134, 62-71.
3) Ye, N.; Shi,P.-Y.; Zhou, J.Therapetic Potential of Spirooxindoles as Antiviral Agents. ACS Infect. Dis.,2016,2, 382-292.
4) Ye, N.; Zhu, Y.; Chen, H.; Liu, Z.; Mei, F. C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure–Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N’-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. J. Med. Chem.,2015, 58, 6033-6047.
5) Ye, N.; Ding, Y.; Wild, C.; Shen, Q.; Zhou, J. Small molecule inhibitors targeting activator protein 1 (AP-1). J. Med. Chem.,2014,57, 6930-6948.
6) Ye, N.; Song, Z.; Zhang, A. Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors as New Antipsychotical or Anti-Parkinsonian Agents. Curr. Med. Chem.,2014,21, 437-457.
7) Ye, N.; Zhou, J. KRAS - An Evolving Cancer Target. Austin J. Cancer Clin. Res.,2014,1, 1004.
8) Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chem. Rev.,2013,113, PR123-178.
9) Ye, N.; Chen, C. H.; Chen, T.; Song, Z.; He, J. X.; Huan, X. J.; Song, S. S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z. H.; Zhang, A. Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. J. Med. Chem.,2013,56, 2885-2903.
10) Ye, N.; Xu, X.; Li, F.; Ning, M.; Liu, Z.; Cao, Y.; Leng, Y.; Zhang, A. Investigation on the Oxidation of Aryl Oxiranylmethanols and the Synthesis of 2-Aryl-N-thiazolyl-oxirane-2-carboxamides as Glucokinase Activators. Tetrahedron Lett.,2012, 53, 4738–4742.
11) Zhang, H.; Ye, N.;^#Zhou, S.; Guo, L.; Zheng, L.; Liu, Z.; Gao, B.; Zhen, X.; Zhang, A.Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson’s Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile. J. Med. Chem.,2011, 54, 4324–4338. (^#并列第一作者)
12) Ye, N.; Wu, Q.; Zhu, L.; Zheng, L.; Gao, B.; Zhen, X.; Zhang, A.Further SAR Study on 11-O-substituted Aporphine Analogues: Identification of Highly Potent Dopamine D3 Receptor Ligands. Bioorg. Med. Chem.,2011, 19, 1999–2008.